Natco Pharma Limited has informed the Exchange about Investor Presentation
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma reported Q1 FY26 (quarter ended 30 June 2025) consolidated total revenue of INR 13,906 Mn, slightly down from INR 14,107 Mn a year ago. EBITDA fell sharply to INR 6,327 Mn with margin compressing to 45.5% from 60.5% in Q1 FY25, as total expenses jumped to INR 7,579 Mn from INR 5,578 Mn. Profit after tax declined to INR 4,803 Mn (EPS of INR 26.84) from INR 6,685 Mn. Export formulations remained the largest segment at INR 11,265 Mn (81% of revenue), while domestic formulations, API, and crop health sciences all grew year-on-year. The company disclosed a strong product pipeline with 28 Para IV filings and 13+ First-to-File opportunities in the US, including Semaglutide (Ozempic/Wegovy), Imbruvica, and Lynparza. Net cash stood healthy at INR 34,740 Mn.
Margins are under significant pressure despite stable revenue, with the EBITDA margin dropping 1,500 bps year-on-year, which is likely to weigh on the stock in the short term. However, the strong product pipeline and net-cash balance sheet of nearly INR 3,474 Cr provide medium-term growth visibility and downside support.